京新药业：公司会努力做好市值管理工作，向投资者正确传达公司的经营情况和临床试验进展

Group 1 - The core viewpoint of the article is that the company, Jingxin Pharmaceutical, is committed to improving its market value management and effectively communicating its operational status and clinical trial progress to investors [2] Group 2 - The company responded to investor inquiries on an interactive platform, indicating its proactive approach to investor relations [2] - Jingxin Pharmaceutical emphasizes the importance of transparency in conveying its business operations and clinical developments [2]